COMMUNIQUÉS West-GlobeNewswire

Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
08/04/2019
— Conference call to be held today at 8:30 a.m. Eastern Time — BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical- [...]
Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal
08/04/2019
Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 87.2% for Jeuveau™, 82.8% for BOTOX ® and 4.2% for Placebo at Day 30 Secondary and Exploratory Analyses Unveil Additional Information about Jeuveau™ [...]
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
08/04/2019
First Clinical Trial to Evaluate the Potential of the Personal Neoantigen Vaccine NEO-PV-01 in Combination with Standard of Care in First-Line Metastatic NSCLC Treatment Setting CAMBRIDGE, Mass., April 08, 2019 (GLOBE [...]
Inspire Medical Systems, Inc. Announces Three New Positive Coverage Policies Issued by Blue Cross Blue Shield Plans
08/04/2019
MINNEAPOLIS, April 08, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]
Emerald Health Therapeutics Receives Standard Processing License for Verdélite Facility in Quebec
08/04/2019
New license gives Verdélite ability to extract and process cannabis for the development and manufacture of next-generation cannabis products VANCOUVER, British Columbia, April 08, 2019 (GLOBE NEWSWIRE) -- Emerald Health [...]
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
08/04/2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus ( [...]
Auxly Announces Receipt of Cultivation and Processing Licences for Robinsons Cannabis Facility
08/04/2019
VANCOUVER, British Columbia, April 08, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (" Auxly " or the " Company ") today announced that its wholly-owned subsidiary, Robinsons Cannabis Inc. (“ [...]
ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
08/04/2019
Data demonstrates that exebacase activates key host factors in human blood to potentiate methicillin-resistant Staphylococcus aureus bacteriolysis YONKERS, N.Y., April 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation [...]
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
08/04/2019
-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution on liver biopsy at 36 weeks -- -- The [...]
Exactus Applauds Executive Chairman, Jonathan Gilbert on Launch of Impact Biosciences Corp.
08/04/2019
DELRAY BEACH, Fla., April 08, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) , a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, applauds its Executive Chairman of the Board, [...]
XOMA Acquires Royalty Rights to Five Hematology Candidates
08/04/2019
EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to acquire the rights to potential royalty payments and a portion of the potential milestone payments [...]
Arrayit Corporation Announces Allergy Testing Services Evaluation Expansion by a Major Pharmacy Retailer
08/04/2019
Sunnyvale, April 08, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces that its proprietary finger stick allergy testing services continue to be [...]
ViroGates notice to convene the annual general meeting on 25 April 2019
08/04/2019
We hereby convene the annual general meeting of ViroGates A/S on 25 April 2019 at 5:00 pm at Comwell Holte, Kongevejen 495A, DK-2840 Holte. The agenda and full proposals can be read in the attached document. For further [...]
TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
08/04/2019
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 08, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of [...]
PCI Biotech: Final confirmation of successful safety read-out in the Phase I Extension study
08/04/2019
Oslo (Norway), 8 April 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced final confirmation of [...]
CLS Releases White Paper Regarding its imILT® Immuno-Stimulating Method for Treating Cancer Tumours at ECIO 2019 Conference
08/04/2019
Technical White Paper Also Available Via the Company’s Website LUND, Sweden, April 08, 2019 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today released a technical white paper regarding the company’ [...]
GN Store Nord A/S issues options to the executive management and key employees
08/04/2019
In accordance with section 3.3.10 of the Nasdaq Copenhagen Rules for Issuers of Shares and with reference to the Remuneration Policy, including General Guidelines for Incentive Pay approved at the annual general meeting [...]
Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
08/04/2019
Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance Paris – April 8, 2019 – Sanofi and Alnylam have agreed to conclude the research and option phase of the companies’ 2014 RNAi [...]
Genkyotex to Present Updated Interim Results From Phase 2 Trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL International Liver Congress (ILC)
08/04/2019
Interim results selected for oral presentation and inclusion in “Best of ILC” summary All patients have completed treatment; favorable safety profile with no drop outs or treatment interruptions due to pruritus Final [...]

Pages